Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Évaluation de l'adhésion aux inhibiteurs du cycle cellulaire utilisés comme traitement adjuvant chez les patientes atteintes d'un cancer du sein localisé à haut risque de récidive. (AdheRA)

29 septembre 2026 mis à jour par: University Hospital, Grenoble

Évaluation de l'adhésion aux inhibiteurs du cycle cellulaire utilisés comme traitement adjuvant chez les patientes atteintes d'un cancer du sein localisé à haut risque de récidive

Hormone receptor-positive (HR+) breast cancers represent the most common histological subtype of breast cancer, accounting for approximately 75% of cases, regardless of HER2 (human epidermal growth factor receptor 2) status (1). Adjuvant endocrine therapy (ET), including tamoxifen and aromatase inhibitors (AIs), is an effective pharmacological treatment for improving the prognosis of HR+ breast cancer, reducing the risk of recurrence by up to 50% (2-3-4-6). Despite its proven prognostic benefit, the full potential of endocrine therapy is not realized due to patient non-adherence (i.e., failure to comply with prescribed treatment). Adjuvant endocrine therapy is generally prescribed for a duration of 5 to 10 years. However, up to 40% of patients discontinue treatment prematurely, and 30% take the medication less frequently than prescribed. Poor adherence and low treatment persistence carry a substantial mortality burden: non-adherence is associated with a 49% increase in all-cause mortality. A retrospective analysis of a large database including more than 8,700 patients showed a 10-year survival rate of 80.7% among women who continued treatment, compared with 73.6% among those who discontinued adjuvant therapy prematurely (p < 0.001). Among patients who continued treatment, the survival rate was 82% in those who were fully adherent, versus 78% in those who were only partially adherent (7-16).

The literature has documented a wide range of risk factors associated with non-adherence to or discontinuation of long-term adjuvant endocrine therapy. Treatment-related adverse effects, including hot flashes, joint stiffness, and sexual dysfunction, are common and may lead to treatment discontinuation. Fear of side effects may also prevent some patients from initiating or maintaining endocrine therapy. Others may not be fully convinced of the necessity of adjuvant endocrine therapy, particularly in the absence of overt signs of cancer. In addition, supportive care required to manage side effects is often inadequately reimbursed, making low income-combined with broader socioeconomic factors-a potential barrier to optimal adherence. Some patients may also experience difficulties remembering to take their medication regularly. The relative importance and contribution of these factors to non-adherence may evolve over time. Other factors may also play a role, including sociodemographic characteristics (low income, living alone, or unemployment).

Nevertheless, a residual risk of recurrence persists after five years of well-conducted standard endocrine therapy, extending up to two decades after diagnosis, particularly in patients with early-stage breast cancer stages II and III. In this higher-risk population, two phase III trials, monarchE and NATALEE, have recently evaluated the addition of a cell cycle inhibitor (CDK4/6 inhibitor) to standard adjuvant endocrine therapy and reported positive results with a reduction in the risk of relapse.

In the NATALEE trial, quality of life was assessed in all patients in the ribociclib plus aromatase inhibitor group (n = 2,549) versus the aromatase inhibitor alone group (n = 2,552). Mean scores did not differ significantly from baseline for any of the analyzed domains. Similarly, no significant change from baseline was observed in either treatment group.

However, it is important to note that 33.8% of patients discontinued ribociclib and 20% discontinued both endocrine therapy and ribociclib in the NATALEE trial, which is consistent with data from the literature.

In the monarchE trial, 16.6% of patients discontinued abemaciclib, and 6% discontinued both abemaciclib and endocrine therapy, while only 0.8% discontinued endocrine therapy in the control group. These findings are not consistent with previously published data.

To our knowledge, no real-world study has evaluated CDK4/6 inhibitors in combination with endocrine therapy in the adjuvant treatment of HR+/HER2-negative breast cancer.

AdheRA is a prospective multicenter cohort study of patients with early-stage HR+/HER2-negative breast cancer at high risk of recurrence, eligible for a combination of endocrine therapy and a CDK4/6 inhibitor such as abemaciclib or ribociclib in the adjuvant setting, aiming to assess treatment adherence and the reasons for non-adherence.

Aperçu de l'étude

Type d'étude

Observationnel

Inscription (Estimé)

81

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

      • Grenoble, France, 38043
        • Recrutement
        • CHU Grenoble Alpes
        • Contact:
        • Contact:
        • Chercheur principal:
          • Emmanuelle JACQUET

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

Patients will be selected from those with localized, high-risk, hormone receptor-positive, HER2-negative breast cancer who are treated at one of the two participating centers and receive adjuvant therapy between 2023 and 2028, and who are eligible for treatment with CDK4/6 inhibitors.

Patients will be seen in dedicated consultations, according to international recommendations, at least every six months, to assess treatment adherence, tolerability, and risk of recurrence. Recruitment will therefore take place directly during these consultations.

All patients for whom an indication for iCDK4/6 therapy is established will be eligible to participate in the study. This indication is determined during multidisciplinary tumor board meetings, which are standard practice in the patient care pathway.

The end of the inclusion period has been arbitrarily set five years later, in order to obtain a sufficient number of patients.

La description

Inclusion Criteria

  • Male or female patients aged ≥18 years.
  • Operable invasive breast carcinoma of no special type, hormone receptor-positive / HER2-negative (estrogen receptor expression >10% with or without progesterone receptor expression >10%; HER2-negative defined as score 0, 1+, or 2+ non-amplified).
  • M0 disease according to the TNM 2018 classification.
  • Having undergone curative surgery of the primary breast tumor.
  • Having received adjuvant radiotherapy, if indicated.
  • Indication for combined adjuvant endocrine therapy and iCDK4/6 therapy validated during a multidisciplinary tumor board meeting.
  • Initiation of adjuvant endocrine therapy combined with a CDK4/6 inhibitor between June 2023 and June 2028.
  • No objection to participation in the study.
  • Affiliation with the national health insurance system.

Non-Inclusion Criteria

  • Medical, geographical, sociological, psychological, or legal conditions that could prevent the patient from completing the study or from providing informed non-opposition.
  • Locally advanced, non-operable disease or metastatic disease not amenable to curative-intent treatment

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: COHORT
  • Perspectives temporelles: PROSPECTIVE

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
The primary objective of this study is to evaluate adherence to iCDK4/6 treatment in patients with localized hormone receptor-positive breast cancer at high risk of recurrence, within a real-world setting.
Délai: Early discontinuation is defined as cessation of treatment prior to 20 months (of a planned 24-month duration) for abemaciclib or prior to 30 months (of a planned 36-month duration) for ribociclib.

The percentage of early discontinuation of iCDK4/6 therapy will be assessed. Early discontinuation is defined as cessation of treatment prior to 20 months (of a planned 24-month duration) for abemaciclib or prior to 30 months (of a planned 36-month duration) for ribociclib.

Early discontinuation is defined as cessation of treatment prior to 20 months (of a planned 24-month duration) for abemaciclib or prior to 30 months (of a planned 36-month duration) for ribociclib.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
The objective is to estimate the proportion of patients who did not initiate iCDK4/6 therapy.
Délai: From day 1 to 2 years for Abemaciclib or 3 years for Ribociclib

The proportion of patients eligible for iCDK4/6 therapy who, in real-world clinical practice, did not initiate treatment.

From day 1 to 2 years for Abemaciclib or 3 years for Ribociclib
To estimate the mean treatment completion rate for iCDK4/6 therapy and endocrine therapy.
Délai: From day 1 to 2 years for Abemaciclib or 3 years for Ribociclib

2a. Percentage of completion of iCDK4/6 therapy (over the planned 2- or 3-year duration).

2b. Percentage of completion of endocrine therapy (over the planned 5-year duration, minimum required).

2c. Median duration of endocrine therapy and iCDK4/6 therapy.

From day 1 to 2 years for Abemaciclib or 3 years for Ribociclib
To estimate the proportion of dose modifications and to describe the reasons for these modifications.
Délai: From day 1 to 2 years for Abemaciclib or 3 years for Ribociclib.

3a. Percentage of patients who experienced a dose reduction of iCDK4/6 therapy. 3b. Assessment of the reasons for iCDK4/6 dose reductions. 3c. Assessment of the reasons for iCDK4/6 treatment discontinuation.

From day 1 to 2 years for Abemaciclib or 3 years for Ribociclib.
To describe risk factors associated with non-adherence.
Délai: From day 1 to 2 years for Abemaciclib or 3 years for Ribociclib

Collection and description of factors associated with non-adherence, including adverse events, physical activity, and sociodemographic factors.

From day 1 to 2 years for Abemaciclib or 3 years for Ribociclib
To evaluate invasive disease-free survival.
Délai: From day 1 to 2 years for Abemaciclib or 3 years for Ribociclib

Evaluation of invasive disease-free survival (iDFS).

From day 1 to 2 years for Abemaciclib or 3 years for Ribociclib

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Emmanuelle JACQUET, University Hospital, Grenoble

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

26 mai 2026

Achèvement primaire (Estimé)

1 avril 2031

Achèvement de l'étude (Estimé)

1 décembre 2031

Dates d'inscription aux études

Première soumission

26 janvier 2026

Première soumission répondant aux critères de contrôle qualité

26 février 2026

Première publication (Réel)

2 mars 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

2 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

29 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 38RC25.0403
  • 2025-A02911-48 (Autre identifiant: ID RCB)

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner